“[Cost-Effectiveness Analysis of Maribavir in Patients With Post-Transplant Cytomegalovirus Infection or Disease That Are Refractory or Resistant to Conventional Therapy]”. 2023. Farmeconomia. Health Economics and Therapeutic Pathways 24 (1). https://doi.org/10.7175/fe.v24i1.1548.